Pulmocide
Biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and chronic respiratory diseases, with a focus on pulmonary fungal infections.
Website
https://www.pulmocide.comLocation
London, United Kingdom
Founded
2013
Investors
1
Categories
biotech, respiratory, antifungal, pulmonary-infections
Notes
Pulmocide is developing novel inhaled therapies for patients suffering from serious acute and chronic respiratory diseases. The company's approach focuses on delivering drugs directly to the lungs through inhalation, particularly targeting pulmonary fungal infections that affect immunocompromised patients.
Pulmocide's lead programs address serious respiratory conditions including pulmonary aspergillosis, which affects patients with weakened immune systems.
Team
- Garth Rapeport, M.D. - Chief Executive Officer
Additional Research Findings
- Founded in 2013 in London, UK
- Focus on inhaled antifungal therapies
- Lead program PC945 (opelconazole) for pulmonary aspergillosis
- Targeting immunocompromised patients with lung infections
- Inhaled delivery for local lung exposure
- European biotech with global development plans
- Addressing serious unmet need in respiratory infections
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Adjuvant Capital | Washington, DC, USA | biotech-focused | seedseries-a+3 | 16 |